Merck Unveils Global Access Plan for Once-Monthly HIV PrEP Pill in Phase 3
MRK sits 67% above its 52-week low of $76.66.
Summary
Merck announced early access plans for alimatravir, its investigational once-monthly oral HIV PrEP drug in Phase 3 trials. The strategy includes royalty-free voluntary licensing with seven generic manufacturers—Aspen, Qcil, UCL Kenya, Aurobindo, Cipla, Emcure, and Viatris—covering 129 low- and middle-income countries. The company is also supporting regional manufacturing in Africa and Latin America and investing early in production to speed availability if approved. This proactive move, before Phase 3 enrollment completes, aims to address the gap where only 3.5 million of the 20 million targeted people used PrEP in 2023. It signals confidence in the drug's prospects and could strengthen Merck's HIV franchise, though approval is not guaranteed. The announcement comes ahead of the International AIDS Conference and follows a series of positive pipeline updates, including recent FDA approvals for Keytruda combinations and LIPFENDRA.
At the time of this announcement, MRK was trading at $127.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $322.3B. The 52-week trading range was $76.66 to $131.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.